Cagrilintide: Exploring the Science Behind a Long-Acting Amylin Analogue
What is cagrilintide?
Cagrilintide is an investigational, long-acting analogue of amylin—a naturally occurring peptide hormone released alongside insulin by pancreatic beta cells after food intake. Amylin participates in several physiological processes associated with energy regulation, including signalling satiety, influencing gastric emptying and regulating post-meal glucagon secretion.
Natural amylin has a short duration of action and can be difficult to formulate because of its tendency to aggregate. Cagrilintide was developed with structural modifications intended to improve stability and extend its activity, making once-weekly investigation possible in clinical studies.
How does cagrilintide differ from GLP-1 receptor agonists?
Cagrilintide is not a GLP-1 receptor agonist. It acts through amylin and calcitonin-family receptors, whereas compounds such as semaglutide primarily target the GLP-1 receptor.
Although the pathways are distinct, both are involved in appetite and metabolic regulation. This complementary biology is why researchers are studying cagrilintide both on its own and together with semaglutide in a fixed-dose investigational combination known as CagriSema.
Why is cagrilintide attracting research interest?
Scientific interest in cagrilintide centres on the amylin pathway and its potential role in body-weight regulation and metabolic health. A randomised phase 2 trial published in The Lancet evaluated once-weekly cagrilintide in adults with overweight or obesity. The study reported dose-dependent reductions in body weight over 26 weeks and supported further clinical development of the compound.
Later studies investigated the co-administration of cagrilintide and semaglutide. Phase 1b and phase 2 research suggested that targeting the amylin and GLP-1 pathways together could produce complementary effects. Phase 3 research on CagriSema has since expanded the evidence base, but findings involving the combination should not be attributed to cagrilintide alone.
What does the amylin pathway do?
Amylin is part of the body's integrated response to nutrient intake. Its known physiological roles include:
-
contributing to satiety signalling in the brain;
-
slowing gastric emptying under certain conditions;
-
moderating post-meal glucagon release; and
-
working alongside insulin in the regulation of nutrient handling.
Cagrilintide is useful to researchers because its longer-acting design allows these mechanisms to be studied over a more practical experimental timeframe than native amylin.
Cagrilintide and CagriSema are not the same compound
The names are sometimes used interchangeably online, but they describe different research subjects:
-
Cagrilintide is the long-acting amylin analogue studied as a single investigational agent.
-
CagriSema is an investigational fixed-dose combination of cagrilintide and semaglutide.
When reviewing published results, it is important to identify whether a study examined cagrilintide alone or the combination. Results from CagriSema trials cannot establish what cagrilintide would achieve independently.
What remains unknown?
Despite encouraging research findings, cagrilintide remains an investigational compound. Questions concerning long-term outcomes, ideal clinical positioning, comparative performance and rare or delayed adverse effects require continued study.
Clinical trials have reported gastrointestinal adverse events, including nausea, among the commonly observed effects. Safety findings depend on the study population, dose, treatment duration and whether cagrilintide was investigated alone or with another compound. Research results should therefore be interpreted in their original study context rather than generalised beyond the evidence.
The importance of research quality
Reliable peptide research depends on clearly identified materials, appropriate controls, validated analytical methods and careful record-keeping. Researchers should review batch-specific documentation and verify that the material selected is suitable for the intended laboratory protocol.
Biolabs Research makes batch Certificates of Analysis available through our COA page, allowing researchers to review the documentation associated with relevant batches.
Conclusion
Cagrilintide represents an important area of current metabolic research because it approaches energy regulation through the amylin pathway rather than the better-known GLP-1 pathway. Its long-acting design, distinct mechanism and investigation both alone and in combination with semaglutide have made it a prominent subject in peptide and metabolic science.
As the evidence develops, careful separation of preclinical findings, single-agent trials and combination studies will remain essential. Cagrilintide should be understood as an investigational research compound—not as an established or approved treatment.
References
-
Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled phase 2 trial. The Lancet. 2021. https://pubmed.ncbi.nlm.nih.gov/34798060/
-
Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in participants with type 2 diabetes: a multicentre, randomised, double-blind, phase 2 trial. The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37364590/
-
Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/40544433/
-
D'Ascanio AM, et al. A long-acting amylin analog for the treatment of obesity. Current Obesity Reports. 2024. https://pubmed.ncbi.nlm.nih.gov/36883831/
Research-use notice: This article is provided for scientific and educational purposes only. Cagrilintide is an investigational compound and is not presented as an approved medicine